NRG Therapeutics' mission and therapeutic theory for neurodegenerative disease
NRG Therapeutics' core story did not materially change between February 27, 2024 and February 16, 2025. In both snapshots, the company argues that neurodegenerative diseases such as Parkinson's and ALS can be tackled by restoring mitochondrial function, and in both it frames that approach as a route to disease-modifying treatment rather than symptom control. The central therapeutic theory stayed fixed: mitochondrial dysfunction sits close enough to the disease process that fixing it could slow or halt progression. What did change is mostly emphasis and presentation. The 2024 language is slightly more direct about the scientific claim, saying these diseases can be addressed through therapies that restore mitochondrial function. The 2025 language broadens the corporate framing, adding that NRG is a neuroscience-focused drug discovery company committed to patients with debilitating neurodegenerative disorders. That is a change in packaging, not in doctrine. Evidence is thin because both entries come from company website snapshots, and both are high-level mission statements. We do not see a public reversal, narrowing of indication, or new mechanistic thesis here. We also do not get much detail on which mitochondrial targets matter most, why NRG thinks this will work in Parkinson's versus ALS, or whether the company became more selective internally. Based on the material here, the belief stayed stable and the wording became a little more polished.